1Isomaa B, Almgren P, Tuomi T, et al. Cardiovascularmorbidity and mortality associated with the metabolic syndrome[J]. Diabetes Care,2001,24:683 - 689.
2Ridker PM,Burning JE,Cook NR,et al. C- reactive Protein, the metabolic syndrome, and risk of incident cardiovascular events. An 8 - year follow - up of 14719 initially healthy A- merican women[J]. Circulation, 2003,107 : 391 - 397.
3Volanakis JE. Human C- reactive protein: expression, structure and function[J]. Mol Immunol, 2001,38(2 - 3) : 189 - 197.
4Fests AD, Agostino R Jr, Howard G, et al. Chronic subclinica inflammation as part of insulin resistance syndrome[J].Circu lation,2000,102 : 42 - 47.
7International Diabetes Federation. The IDF consensus worldwide definition ofthe metabolic syndrome[OL]. Available at: www. IDF. org. Accessed April 14,2005.
8Scott MG,James IC,Stephen RD, et al. Diagnosis and management of themetabolic syndrome. An American Heart Association/National Heart, Lung, and BloodInstitute Scientific Statement[J]. Circulation, 2005,112 : 2735 - 2752.
6King H, Roglie G. Global status of diabetes and recommendations for international action [J]. Intenational Diabetes Monitor, 1999, 11 : 38-45.
7American Diabetes Association. Report of the export committee on the diagnosis and classification of diabetes mellitus [J]. Diabetes Care, 1997, 20: 1183-1197.
8Gu D, Reynolds K, Duan X, et al. Prevalence of diabetes and impaired fasting glucose in the Chinese adult population: International Collaborative Study of Cardiovascular Disease in Asia [J]. Diabetologia, 2003, 46 (9): 1190-1198.
7Scott MG, James IC, Stephen RD ,et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung,and Blood Institute Scientific Statement [ J]. Circulation, 2005; 112:2735-52.
